Lineage Cell Therapeutics, Inc.
LCTX
$1.61
$0.031.90%
AMEX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 6.61M | 3.68M | 2.77M | 1.50M | 2.87M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.61M | 3.68M | 2.77M | 1.50M | 2.87M |
| Cost of Revenue | 211.00K | 184.00K | 3.15M | 2.98M | 324.00K |
| Gross Profit | 6.40M | 3.50M | -380.00K | -1.48M | 2.54M |
| SG&A Expenses | 4.85M | 4.19M | 4.56M | 4.86M | 4.40M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.16M | 7.47M | 7.71M | 8.01M | 7.98M |
| Operating Income | -6.55M | -3.79M | -4.94M | -6.51M | -5.11M |
| Income Before Tax | -4.39M | -29.75M | -30.36M | -4.14M | -3.25M |
| Income Tax Expenses | -5.28M | -- | -- | -- | -- |
| Earnings from Continuing Operations | 892.00K | -29.75M | -30.36M | -4.14M | -3.25M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -41.00K | -29.00K | -100.00K | 4.00K | -23.00K |
| Net Income | 851.00K | -29.78M | -30.46M | -4.14M | -3.27M |
| EBIT | -6.55M | -3.79M | -4.94M | -6.51M | -5.11M |
| EBITDA | -6.36M | -3.61M | -4.77M | -6.34M | -4.96M |
| EPS Basic | 0.00 | -0.13 | -0.13 | -0.02 | -0.01 |
| Normalized Basic EPS | -0.01 | -0.08 | -0.04 | -0.01 | -0.01 |
| EPS Diluted | 0.00 | -0.13 | -0.13 | -0.02 | -0.01 |
| Normalized Diluted EPS | -0.01 | -0.08 | -0.04 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 237.17M | 228.85M | 228.36M | 226.05M | 240.19M |
| Average Diluted Shares Outstanding | 237.17M | 228.85M | 228.36M | 226.05M | 240.19M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |